<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00875771</url>
  </required_header>
  <id_info>
    <org_study_id>TTD-08-03</org_study_id>
    <secondary_id>EudraCT number:2008-004688-20</secondary_id>
    <nct_id>NCT00875771</nct_id>
  </id_info>
  <brief_title>Irinotecan, Capecitabine and Bevacizumab in Metastatic Colorectal Cancer Patients</brief_title>
  <acronym>AVAXIRI</acronym>
  <official_title>Phase II Study of Irinotecan, Capecitabine and Bevacizumab in Metastatic Colorectal Cancer Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Spanish Cooperative Group for the Treatment of Digestive Tumours (TTD)</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Hoffmann-La Roche</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Spanish Cooperative Group for the Treatment of Digestive Tumours (TTD)</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine efficacy and safety of the biweekly scheme with&#xD;
      Capecitabine and Irinotecan, plus bevacizumab in patients with metastatic colorectal cancer.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The purpose of this study is to determine efficacy and safety of the biweekly scheme with&#xD;
      Capecitabine and Irinotecan, plus bevacizumab in patients with metastatic colorectal cancer.&#xD;
&#xD;
        -  Capecitabine: 1000 mg/m2, bid, oral, days 2-8. Every 2 weeks&#xD;
&#xD;
        -  Irinotecan: 175 mg/m2, iv infusion 90 minutes, day 1, every 2 weeks&#xD;
&#xD;
        -  Bevacizumab: 5 mg/kg day 1, every 2 Weeks&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>April 2009</start_date>
  <completion_date type="Actual">May 2012</completion_date>
  <primary_completion_date type="Actual">May 2012</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Progression free survival (PFS)</measure>
    <time_frame>2009-2012</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>overall survival (SG)</measure>
    <time_frame>2009-2012</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Response rate</measure>
    <time_frame>2009-2012</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Toxicity</measure>
    <time_frame>2009-2012</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of response</measure>
    <time_frame>2009-2012</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life</measure>
    <time_frame>2009-2012</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of hepatic metastases resection</measure>
    <time_frame>2009-2012</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">80</enrollment>
  <condition>Metastatic Colorectal Cancer</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Capecitabine: 1000 mg/m2, bid, oral, days 2-8. Every 2 weeks&#xD;
Irinotecan: 175 mg/m2, iv infusion 90 minutes, day 1, every 2 weeks&#xD;
Bevacizumab: 5 mg/kg day 1, every 2 Weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Capecitabine+Irinotecan+Bevacizumab</intervention_name>
    <description>Capecitabine: 1000 mg/m2, bid, oral, days 2-8. Every 2 weeks&#xD;
Irinotecan: 175 mg/m2, iv infusion 90 minutes, day 1, every 2 weeks&#xD;
Bevacizumab: 5 mg/kg day 1, every 2 Weeks&#xD;
Treatment will be given until disease progression or unacceptable toxicity.</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Age &gt; 18 years old (men and women)&#xD;
&#xD;
          2. ECOG Performance Status ≤ 2.&#xD;
&#xD;
          3. Histologically confirmed colorectal adenocarcinoma, metastatic disease.&#xD;
&#xD;
          4. No surgery option&#xD;
&#xD;
          5. No previous chemotherapy, except adjuvant treatment finished at least 6 months before&#xD;
             the study inclusion&#xD;
&#xD;
          6. Have at least one measurable lesion according to the RECIST criteria&#xD;
&#xD;
          7. At least a 3-month life expectancy.&#xD;
&#xD;
          8. Written informed consent given.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Patients who have previously received systemic treatment (for example, cytostatic&#xD;
             chemotherapy or active/passive immunotherapy) for advanced or metastatic disease.&#xD;
&#xD;
          2. Patients previously treated with bevacizumab&#xD;
&#xD;
          3. Prior adjuvant or neoadjuvant treatment for non-metastatic disease (M0) is allowed, as&#xD;
             long as it has concluded at least 6 months before beginning the treatment of the&#xD;
             study.&#xD;
&#xD;
          4. If adjuvant treatment has previously been administered, the patients cannot have shown&#xD;
             progression of the disease during treatment nor during the 6 months following&#xD;
             termination thereof.&#xD;
&#xD;
          5. Prior radiotherapy is allowed if it has not been administered in the target lesions&#xD;
             selected for this study, unless progression of said lesions in the irradiated field is&#xD;
             documented, and as long as treatment has concluded at least 4 weeks before beginning&#xD;
             the study.&#xD;
&#xD;
          6. Prior surgical treatment of the disease in stage IV is allowed.&#xD;
&#xD;
          7. Only non evaluable disease (non measurable) as ascitis, pleural effusion, diffuse&#xD;
             hepatic, osseous metastasis&#xD;
&#xD;
          8. History of another neoplastic disease during the last five years, with the exception&#xD;
             of cured basal cell carcinoma of the skin and cervical carcinoma in situ.&#xD;
&#xD;
          9. History or indications of CNS disease (for example, primary brain tumor, uncontrolled&#xD;
             convulsions with standard medical treatment, cerebral metastases of any type or&#xD;
             history of ictus) in the physical examination.&#xD;
&#xD;
         10. Medication or peripheral vascular disease, grade II or higher. Furthermore, those&#xD;
             patients who have had a myocardial infarction in the year prior to beginning the&#xD;
             treatment of the study will be excluded.&#xD;
&#xD;
         11. History of psychiatric disability that the investigator considers clinically&#xD;
             significant, which prevents the patient from granting the informed consent or&#xD;
             interferes with compliance of taking the oral medication&#xD;
&#xD;
         12. Clinically significant cardiovascular disease (i.e., active), for example,&#xD;
             uncontrolled hypertension, unstable angina, congestive heart failure, class II or&#xD;
             higher of the New York Heart Association (NYHA), severe cardiac arrhythmia&#xD;
&#xD;
         13. Lack of physical integrity of the upper gastrointestinal tract, malabsorption syndrome&#xD;
             or inability to take oral medication.&#xD;
&#xD;
         14. Patients subjected to organ allografts who require immunosuppressive treatment.&#xD;
&#xD;
         15. Severe, non-cicatrized osseous fractures, wounds or ulcers.&#xD;
&#xD;
         16. Indications of hemorrhagic diathesis or coagulopathy.&#xD;
&#xD;
         17. Severe, uncontrolled intercurrent infections or other severe, uncontrolled concomitant&#xD;
             diseases.&#xD;
&#xD;
         18. Moderate or severe renal failure [creatinine clearance lower than 30 ml/min&#xD;
             (calculated according to the Cockcroft-Gault Formula)] or serum creatinine &gt; 1.5 x&#xD;
             upper limit of normal (ULN).&#xD;
&#xD;
         19. Any of the following laboratory values:&#xD;
&#xD;
               -  Absolute neutrophils count (ANC) ≤ 1.5 x 109/l.&#xD;
&#xD;
               -  Platelet count ≤ 100 x 109/l.&#xD;
&#xD;
               -  Hemoglobin ≤ 9 g/dl.&#xD;
&#xD;
               -  INR &gt; 1.5.&#xD;
&#xD;
               -  Total bilirubin &gt;1.5 ULN.&#xD;
&#xD;
               -  ALS and/or AST &gt; 2.5 x ULN or &gt; 5 x ULN (in case of hepatic metastasis).&#xD;
&#xD;
               -  Alkaline phosphatase &gt; 2.5 x ULN or 5 x ULN (in case of hepatic metastasis), or &gt;&#xD;
                  10 x ULN (in case of bone metastasis).&#xD;
&#xD;
         20. History of unexpected serious adverse events to fluoropyrimidine treatments or known&#xD;
             dihidropyrimidine dehydrogenase (DPD) deficiency.&#xD;
&#xD;
         21. Patients subjected to major surgical procedure, open biopsy or patients have been&#xD;
             significant traumatic injures in 28 days time before the initial study treatment, or&#xD;
             patients with a major surgery procedure planning during the study period. Fine needle&#xD;
             aspiration biopsy 7 days before the initial study.&#xD;
&#xD;
         22. Use of full dose of oral or parenteral anticoagulants ( at least 10 days before the&#xD;
             initial study treatment or thrombolytic agents. Low dose of warfarin is allowed, with&#xD;
             an INR ≤ 1.5&#xD;
&#xD;
         23. Subject requiring chronic use of high dose aspirin (&gt; 325 m/day) or non-steroidal&#xD;
             anti-inflammatory treatment (those known to inhibit platelet function at doses used to&#xD;
             treat chronic inflammatory diseases).&#xD;
&#xD;
         24. Pregnant (serum positive pregnancy test) or lactating women.&#xD;
&#xD;
         25. Received any investigational drug or agent/ procedure, i.e. participation in another&#xD;
             treatment trial within 30 days of randomisation.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Pilar García Alfonso, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Hospital Gregorio Marañón. Madrid. Spain</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Enrique Aranda, MD; phD</last_name>
    <role>Study Chair</role>
    <affiliation>Hospital Reina Sofía. Cordoba. Madrid</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Spanish Cooperative Group for Gastrointestinal Tumour Therapy</name>
      <address>
        <city>Madrid</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <link>
    <url>http://www.ttdgroup.org</url>
    <description>Related Info</description>
  </link>
  <verification_date>July 2017</verification_date>
  <study_first_submitted>March 30, 2009</study_first_submitted>
  <study_first_submitted_qc>April 2, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 3, 2009</study_first_posted>
  <last_update_submitted>July 31, 2017</last_update_submitted>
  <last_update_submitted_qc>July 31, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">August 1, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>metastatic colorectal cancer</keyword>
  <keyword>BEVACIZUMAB</keyword>
  <keyword>CAPECITABINE</keyword>
  <keyword>IRINOTECAN</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Colorectal Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Bevacizumab</mesh_term>
    <mesh_term>Capecitabine</mesh_term>
    <mesh_term>Irinotecan</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

